Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters.

Child Infant Humans Child, Preschool B-Lymphocytes Antibodies, Monoclonal Memory B Cells Immunoglobulin A Paraproteins Epitopes Genotype Norovirus / genetics
GII.17 blockade antibody children human monoclonal antibodies memory B cells norovirus variants of concern

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 26 05 2023
accepted: 25 07 2023
medline: 5 9 2023
pubmed: 4 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

Genogroup II (GII) noroviruses are a major cause of diarrheal disease burden in children in both high- and low-income countries. GII.17 noroviruses are composed of distinct genetic clusters (I, II, IIIa, and IIIb) and have shown potential for replacing historically more prevalent GII.4 strains, but the serological basis for GII.17 antigenic diversity has not been studied in children. Utilizing samples from a birth cohort, we investigated antibody and B-cell responses to GII.17 cluster variants in confirmed GII.17 infections in young children as well as demonstrated that the distinct genetic clusters co-circulate. Polyclonal serum antibodies bound multiple clusters but showed cluster-specific blockade activity in a surrogate virus neutralization assay. Antibodies secreted by immortalized memory B cells (MBCs) from an infant GII.17 case were highly specific to GII.17 and exhibited blockade activity against this genotype. We isolated an MBC-derived GII.17-specific Immunoglobulin A (IgA) monoclonal antibody called NVA.1 that potently and selectively blocked GII.17 cluster IIIb and recognized an epitope targeted in serum from cluster IIIb-infected children. These data indicate that multiple antigenically distinct GII.17 variants co-circulate in young children, suggesting retention of cluster diversity alongside potential for immune escape given the existence of antibody-defined cluster-specific epitopes elicited during infection.

Identifiants

DOI: 10.3389/fimmu.2023.1229724 PMID: 37662930 PMC: PMC10471973
pubmed: 37662930
doi: 10.3389/fimmu.2023.1229724
pmc: PMC10471973
doi:

Substances chimiques

Antibodies, Monoclonal 0
Immunoglobulin A 0
Paraproteins 0
Epitopes 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1229724

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI141744
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI148260
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM118228
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010923
Pays : United States
Organisme : NIH HHS
ID : S10 OD018175
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI152039
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127845
Pays : United States

Informations de copyright

Copyright © 2023 Strother, Brewer-Jensen, Becker-Dreps, Zepeda, May, Gonzalez, Reyes, McElvany, Averill, Mallory, Montmayeur, Costantini, Vinjé, Baric, Bucardo, Lindesmith and Diehl.

Déclaration de conflit d'intérêts

LCL and RSB hold patents on norovirus vaccine design and ongoing collaborations with Vaxart, Takeda Vaccines, HilleVax, and BioNTech. RSB is a member of the advisory committee for Vaxart and Invivyd. SB-D and SAD received investigator-initiated research awards, respectively. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Infect Dis. 2014 Dec 1;210(11):1755-62
pubmed: 24970849
Emerg Microbes Infect. 2021 Dec;10(1):954-963
pubmed: 33929932
Nat Med. 2010 Jan;16(1):123-8
pubmed: 20023635
Nat Commun. 2021 Jul 14;12(1):4320
pubmed: 34262046
J Virol. 2002 Dec;76(23):12335-43
pubmed: 12414974
Emerg Infect Dis. 2017 Aug;23(8):1359-1354
pubmed: 28726618
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9175-80
pubmed: 18599458
Euro Surveill. 2015 Jul 02;20(26):
pubmed: 26159308
Emerg Infect Dis. 2018 Aug;24(8):1453-1464
pubmed: 30014841
Curr Protoc Microbiol. 2013 Nov 05;31:15K.1.1-15K.1.45
pubmed: 24510290
J Immunol Methods. 2016 Nov;438:67-70
pubmed: 27600311
J Infect Dis. 2010 Oct 15;202(8):1212-8
pubmed: 20815703
J Virol. 2018 May 14;92(11):
pubmed: 29540599
Infect Genet Evol. 2017 Jan;47:121-124
pubmed: 27908796
PLoS Pathog. 2012;8(5):e1002705
pubmed: 22615565
Infect Genet Evol. 2021 Dec;96:105135
pubmed: 34781036
J Clin Microbiol. 2017 Jul;55(7):2208-2221
pubmed: 28490488
PLoS Med. 2015 Mar 24;12(3):e1001807
pubmed: 25803642
Infect Dis Clin North Am. 2018 Mar;32(1):103-118
pubmed: 29406972
N Engl J Med. 2011 Dec 8;365(23):2178-87
pubmed: 22150036
J Microbiol. 2014 Nov;52(11):970-5
pubmed: 25277406
Emerg Infect Dis. 2021 May;27(5):1438-1445
pubmed: 33900173
J Clin Virol. 2021 Jan;134:104689
pubmed: 33260046
J Med Virol. 2022 Aug;94(8):4005-4011
pubmed: 35383971
J Infect Dis. 2017 Mar 15;215(6):984-991
pubmed: 28453838
JCI Insight. 2019 Apr 18;4(8):
pubmed: 30996133
Pediatr Infect Dis J. 2009 Sep;28(9):844-7
pubmed: 19636281
Science. 1999 Oct 8;286(5438):287-90
pubmed: 10514371
Clin Exp Immunol. 2010 Nov;162(2):271-9
pubmed: 20854328
J Gen Virol. 2019 Oct;100(10):1393-1406
pubmed: 31483239
J Infect Dis. 2020 May 11;221(11):1864-1874
pubmed: 31957785
Pediatr Infect Dis J. 2021 Mar 1;40(3):220-226
pubmed: 33464013
Infect Genet Evol. 2017 Jul;51:28-32
pubmed: 28300648
Curr Opin Infect Dis. 2018 Oct;31(5):422-432
pubmed: 30102614
EBioMedicine. 2019 Mar;41:465-478
pubmed: 30857944
J Virol. 2014 Jan;88(2):829-37
pubmed: 24173225
Viruses. 2019 May 10;11(5):
pubmed: 31083353
Clin Infect Dis. 2014 Feb;58(4):483-91
pubmed: 24300042
J Infect Dis. 2017 Dec 5;216(10):1227-1234
pubmed: 28973354
J Virol. 2012 Jan;86(2):873-83
pubmed: 22090098
Viruses. 2022 Sep 16;14(9):
pubmed: 36146859
Clin Vaccine Immunol. 2017 May 5;24(5):
pubmed: 28249841
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997294
J Immunol. 2015 Dec 1;195(11):5159-68
pubmed: 26503953
J Gen Virol. 2014 Feb;95(Pt 2):278-291
pubmed: 24243731
J Virol. 2013 May;87(9):4818-25
pubmed: 23408637
Cell Rep Med. 2020 Dec 22;1(9):100155
pubmed: 33377126
Food Environ Virol. 2018 Mar;10(1):16-28
pubmed: 28779481
Nat Protoc. 2009;4(3):372-84
pubmed: 19247287
Emerg Infect Dis. 2015 Aug;21(8):1477-9
pubmed: 26196235
Clin Vaccine Immunol. 2015 Feb;22(2):168-77
pubmed: 25428246
Nat Commun. 2021 Feb 17;12(1):1102
pubmed: 33597521
J Infect Dis. 2017 Feb 1;215(3):351-358
pubmed: 27932620
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34003796
J Virol. 1992 Nov;66(11):6527-32
pubmed: 1328679
J Clin Virol. 2021 Jan;134:104718
pubmed: 33360859
J Gen Virol. 2014 Sep;95(Pt 9):1958-1968
pubmed: 24899153
PLoS Med. 2008 Feb;5(2):e31
pubmed: 18271619
Immunity. 2019 Jun 18;50(6):1530-1541.e8
pubmed: 31216462
Lancet Infect Dis. 2014 Aug;14(8):725-730
pubmed: 24981041
mBio. 2022 Oct 26;13(5):e0186122
pubmed: 36102514
Viruses. 2019 Jun 08;11(6):
pubmed: 31181749
Lancet Glob Health. 2018 Dec;6(12):e1319-e1328
pubmed: 30287125
J Virol. 2009 Jun;83(11):5363-74
pubmed: 19297483
Clin Infect Dis. 2021 Jan 27;72(2):222-229
pubmed: 33501947
Sci Transl Med. 2019 Feb 27;11(481):
pubmed: 30814336
J Pediatric Infect Dis Soc. 2022 Oct 25;11(10):459-462
pubmed: 35849117
PLoS Pathog. 2017 Jan 19;13(1):e1006136
pubmed: 28103318

Auteurs

Camilla A Strother (CA)

Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States.
Cellular, Molecular, and Biomedical Sciences Graduate Program, University of Vermont, Burlington, VT, United States.
Translational Global Infectious Disease Research Center, Larner College of Medicine, University of Vermont, Burlington, VT, United States.

Paul D Brewer-Jensen (PD)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Sylvia Becker-Dreps (S)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Omar Zepeda (O)

Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua.

Samantha May (S)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Fredman Gonzalez (F)

Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua.

Yaoska Reyes (Y)

Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua.

Benjamin D McElvany (BD)

Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States.

April M Averill (AM)

Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States.

Michael L Mallory (ML)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Anna M Montmayeur (AM)

National Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Verónica P Costantini (VP)

National Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Jan Vinjé (J)

National Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Ralph S Baric (RS)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Filemon Bucardo (F)

Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua.

Lisa C Lindesmith (LC)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Sean A Diehl (SA)

Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States.
Cellular, Molecular, and Biomedical Sciences Graduate Program, University of Vermont, Burlington, VT, United States.
Translational Global Infectious Disease Research Center, Larner College of Medicine, University of Vermont, Burlington, VT, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Infant antibody and B-cell responses following...
questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Infant antibody and B-cell responses following...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Infant antibody and B-cell responses following...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › Infant antibody and B-cell responses following...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Infant antibody and B-cell responses following...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Infant antibody and B-cell responses following...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Sous-populations de lymphocytes B › Cellules B mémoire › Infant antibody and B-cell responses following...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline A › Infant antibody and B-cell responses following...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Paraprotéines › Infant antibody and B-cell responses following...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Infant antibody and B-cell responses following...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Infant antibody and B-cell responses following...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Caliciviridae › Norovirus › Infant antibody and B-cell responses following...